



COUNTRY PROFILE

Uganda

EDCTP participation



Uganda in EDCTP

(2003-present)

Uganda in EDCTP: key figures

Since 2003, Uganda has become a leading EDCTP partner through strong research leadership, capacity building, and international collaboration.



171

Projects involving Uganda-based entities or fellows



48

Uganda-based entities involved in EDCTP-funded projects



57

Collaborating countries with Uganda-based entities through EDCTP-funded projects



25

Consortia-based projects coordinated by Uganda entities



20

Global Health EDCTP3 projects with Uganda-based **scientific leadership***



€111.2 M

EDCTP funding attributed to Uganda-based entities


M = million

* Project scientific leader role was introduced in the [Work Programme 2023](#) and implemented in projects funded as of 2024

Uganda in EDCTP: participation over time

Uganda's participation expanded sharply under EDCTP2 and remains strong in Global Health EDCTP3, with current funding already at comparable levels while the programme is still ongoing.

Uganda participation across EDCTP iterations




TMA = Training and Mobility Action; **RIA** = Research and Innovation Action; **CSA** = Coordination and Support Action. EDCTP1 used 10 original funding categories, which were regrouped here under TMA, RIA and CSA equivalents for over-time comparability. In Global Health EDCTP3, CSAs may include fellowship components, but not direct individual fellowship grants as under the TMA model in EDCTP1 and 2

Uganda in EDCTP: participating organisations

Uganda's EDCTP participation is driven by a strong institutional ecosystem, combining universities, national research organisations, clinical research centres, and public-health bodies.

Top 20 Uganda-based entities by EDCTP funding




M = million

Uganda in EDCTP: international collaboration

Since 2003, Uganda has built one of EDCTP's broadest collaboration networks, strongly rooted in Africa, and linked globally.

57 collaborating countries: **35** in Africa | **16** in Europe | **6** in other world regions

Top 20 partner countries by number of collaborating Ugandan entities



Geographical spread of Uganda's EDCTP collaboration links



Uganda in EDCTP country rankings

Across the full period since 2003, Uganda ranks **3rd** by grant funding received and **4th** by number of participating entities.

Top 20 countries by EDCTP grant amounts

Country	Value	Rank
South Africa	€ 216.9 M	1
United Kingdom	€ 184.6 M	2
Uganda	€ 111.2 M	3
United Republic of Tanzania	€ 95.1 M	4
Kenya	€ 84.1 M	5
Germany	€ 74.5 M	6
France	€ 73.4 M	7
Netherlands	€ 58.6 M	8
Spain	€ 58.3 M	9
Burkina Faso	€ 51.3 M	10
Mozambique	€ 49.8 M	11
Switzerland	€ 44.3 M	12
Zambia	€ 42.7 M	13
Ghana	€ 42.3 M	14
Mali	€ 38.0 M	15
Senegal	€ 35.4 M	16
Gabon	€ 33.0 M	17
Ethiopia	€ 32.0 M	18
Democratic Republic of The Congo	€ 32.0 M	19
Belgium	€ 30.1 M	20

Top 20 countries by number of participating entities

Country	Value	Rank
United Kingdom	57	1
France	50	2
South Africa	50	2
Uganda	48	3
Spain	43	4
Kenya	42	5
Germany	37	6
Nigeria	36	7
Netherlands	34	8
Italy	33	9
United Republic of Tanzania	31	10
Ethiopia	29	11
Switzerland	25	12
United States	24	13
Cameroon	19	14
Rwanda	18	15
Belgium	17	16
Burkina Faso	16	17
Ghana	16	17
Democratic Republic of The Congo	15	18

Uganda's wider contribution to EDCTP

Beyond project participation, Uganda supports EDCTP through financial contributions, aligned national activities, and project co-investment.

€65.4 M aligned in-kind investments

Value of in-kind activities implemented by Uganda in support of EDCTP Programme objectives

€9.0 K in-cash contribution

Uganda's contribution to the EDCTP Association, 2023-2025

Aligned in-kind activities

- **Presidential Scientific Initiative on Epidemics (PRESIDE):** Government-funded (€19.5 million) initiative supporting three COVID-19 vaccine trials and isolation of circulating SARS-CoV-2 variants, complemented by pathogen genomics partnerships, including the Gates Foundation.
- **Makerere University Research and Innovation Fund:** Mobilised approximately €24 million for research addressing national priorities, strengthening research capacity and supporting early-career researchers. Funded projects include plant-based mosquito repellents and a respiratory clinical study informing Uganda's national oxygen policy.

Impact example: paediatric schistosomiasis treatment

Uganda's Ministry of Health led the implementation of arpraziquantel, the first schistosomiasis medicine designed for young children, generating critical evidence to support its rollout.

Story

Co-funded by EDCTP, the [ADOPT programme](#) helped prepare for the large-scale delivery of arpraziquantel by assessing community acceptance, social mobilisation, drug delivery strategies, and monitoring and evaluation frameworks in Kenya, Côte d'Ivoire, and Uganda. Researchers from Uganda's Ministry of Health provided critical scientific leadership in the project.

What changed

EDCTP supported the development of arpraziquantel, a medicine included in the WHO Model List of Essential Medicines for Children, as well as the follow-up research needed for its rollout and wider adoption in real-world settings, generating evidence of its suitability for children under six. Uganda was among the first countries to pilot arpraziquantel, generating critical real-world evidence on its efficacy and tolerability.

Why this matters

Schistosomiasis affects 240 million people worldwide and can cause lifelong disability and death. Arpraziquantel could help protect up to 50 million at-risk children. Ugandan institutions played a key role in making this new treatment accessible.

[Treatment rollout, Uganda, March 2025 | Pediatric Praziquantel Consortium](#)

EDCTP's contribution included:

- ✓ support to the clinical development and research on the implementation and large-scale access of arpraziquantel
- ✓ support to capacity development and networks

Child-friendly arpraziquantel for paediatric schistosomiasis



Impact example: enabling new medicines for uncomplicated malaria

Ugandan researchers contributed to the 4ABC trials, which identified effective antimalarial drug combinations for treating uncomplicated malaria in young children and supported the development of a new antimalarial medicine (Eurartesim).

Story

EDCTP funded a key clinical study that established the safety, dosing and effectiveness of dihydroartemisinin-piperazine (DHAPQ), including in young children and people living with HIV. The project also demonstrated that two additional artemisinin-based combination therapies (ACTs) were safe and effective for treating children with uncomplicated malaria. Researchers from the Mbarara University of Science and Technology, Makerere University, and the Uganda Malaria Surveillance Program at the Ministry of Health contributed to this research.

What changed

This evidence supported WHO recommendations and EMA regulatory approval of Eurartesim®. Today, WHO-prequalified DHAPQ is included in country treatment guidelines and widely used across Africa and Asia as an ACT for uncomplicated malaria.

Why this matters

Malaria remains a major cause of illness and death among African children. When uncomplicated malaria is left untreated or inadequately treated, it can rapidly progress to severe disease and death.

EDCTP's contribution included:

- ✓ support to multicountry efficacy trials to assess the safety and effectiveness of four artemisinin-based combination therapies (ACTs)
- ✓ Building capacity to improve product uptake

[Head-to-Head Comparison of Four Artemisinin-Based Combinations for Treating Uncomplicated Malaria in African Children: A Randomized Trial | PLOS Medicine](#)



WHO-
recommended



EMA-
approved



EDCTP fellowship supporting scientific leadership

Prof. Pauline Byakika-Kibwika's EDCTP fellowship supported malaria-HIV research; in 2024, she became Vice-Chancellor of Mbarara University of Science and Technology.



Prof. Pauline Byakika-Kibwika

Physician and infectious disease specialist | EDCTP2
Senior Fellow, 2018-2023

Optimising treatment for malaria-HIV co-infection

As an EDCTP2 Senior Fellow from 2018 to 2023, she studied how interactions between antimalarial and antiretroviral medicines can affect malaria treatment outcomes where HIV and malaria co-exist.

Strengthening clinical pharmacology expertise

Her work generated evidence on treatment effectiveness, pharmacokinetics, and safer dosing strategies for people with malaria-HIV co-infection.

Academic leadership

After a long-standing academic career at Makerere University College of Health Sciences, she was appointed Vice-Chancellor of Mbarara University of Science and Technology in 2024.

Prof. Pauline Byakika-Kibwika: [inspiring women in health research](#)



TB research and academic leadership

Dr David Kateete's EDCTP fellowship advanced TB microbiome research and team development; by its end, he had been promoted to Associate Professor and appointed Dean.



Dr David Kateete

Molecular biologist from Uganda | EDCTP Career Development Fellow in tuberculosis microbiome research

Developing expertise in tuberculosis research

His MTI-Plus fellowship investigated the role of the microbiome in TB disease dynamics in a setting with high HIV prevalence.

Building the next generation of researchers

The fellowship supported two Master's trainees and a PhD trainee and helped establish a multidisciplinary research team.

Progressing into academic leadership

Building on the fellowship, Dr Kateete's team secured an NIH grant, while he was promoted to Associate Professor and appointed Dean of the School of Biomedical Sciences.

Dr David Kateete story: [inspiring health research](#)



Research leadership and capacity

Prof. Peter Olupot-Olupot combined research leadership in Uganda with regional training for outbreak preparedness.



Prof. Peter Olupot-Olupot

Clinical and infectious disease epidemiologist | EDCTP Senior Fellow, 2018-2023

Strengthening research capacity in Uganda

His EDCTP Senior Fellowship (2018-2023) strengthened research leadership and institutional capacity at Mbale Clinical Research Institute.

Building regional expertise

He led the EDCTP-Africa CDC IDEA Fellowship programme, which aimed to train 150 epidemiologists and biostatisticians across sub-Saharan Africa.

Supporting outbreak response

During COVID-19, he established a testing laboratory in Mbale to support Uganda's national response.

Read the story: Prof. Peter Olupot-Olupot story: [inspiring health research](#)



Uganda in Global Health EDCTP3

(2021-present)

Uganda in Global Health EDCTP3: key figures

Since 2021, Uganda-based entities have reinforced the country’s role as a major African research hub, contributing local expertise to continental health priorities and global health challenges.

51

Funded **projects** with Uganda-based participation

20

Projects with **scientific leadership*** by Uganda-based entities

21

Uganda-based **entities** participating in funded projects


47

Countries collaborating with Uganda-based entities through funded projects


€46.9 M

JU grant **funding** awarded to Uganda-based entities

Uganda participating entities by grant amounts



Uganda participating entities by type




* Project scientific leader role was introduced in the [Work Programme 2023](#) and implemented in projects funded as of 2024

Uganda in Global Health EDCTP3: international network

Since 2021, Uganda has continued to act as a major EDCTP collaboration hub across Africa, Europe, and beyond.

47 collaborating countries: **27** in Africa | **15** in Europe | **5** in other world regions

Top 20 partner countries by number of collaborating Ugandan entities



Geographical spread of Uganda’s Global Health EDCTP3 collaboration links



Uganda in governance and advisory structures

Ugandan experts contribute to EDCTP's decision-making and scientific advice.

GOVERNANCE

2 representatives in the EDCTP Association General Assembly

Dr Sam Okware

Public health, epidemiology and HIV/AIDS control

Uganda National Health Research Organisation (UNHRO)

Prof. Pontiano Kaleebu

HIV virology, vaccine research and immunology

Uganda Virus Research Institute (UVRI)

ADVISORY

2 Ugandan experts in the Global Health EDCTP3 Stakeholders' Group

Prof. Pauline Byakika-Kibwika Chairperson

Infectious diseases, clinical epidemiology and malaria-HIV pharmacology

Interdisciplinary Consortium for Epidemics Research (ICER)

Prof. Wilber Sabiiti Alternate

Tuberculosis, molecular diagnostics and antimicrobial resistance

Interdisciplinary Consortium for Epidemics Research (ICER)



2014

Uganda joined the EDCTP Association

Project highlight: DECIPHER-MPOX

A Ugandan university provides scientific leadership in a project identifying factors linked to mpox susceptibility and disease severity.

The challenge:

- It is unclear why exposure to mpox leads to different outcomes and the factors that influence susceptibility and disease severity.

Expected impact:

- Follow mpox patients and their family contacts in the DRC to identify factors linked to infection risk and disease severity.
- Analyse human genetics, immune responses, and viral strains to understand why some people are more susceptible to severe mpox than others.



Coordinator:
National Health Laboratory Services,
South Africa

Scientific leader:
Makerere University, Uganda

Countries: **South Africa, Canada, DRC,**
Uganda, UK

Funding: **€1,260,000**

Project length: **2024 – 2027**

https://www.global-health-edctp3.europa.eu/projects/decipher-mpox_en

Project highlight: MpoxVax AFRIVAC

A Ugandan university research institute provides scientific leadership to evaluate MVA-BN mpox vaccine immunity in African populations.

The challenge:

- Limited evidence on MVA-BN vaccine immune response strength, durability, and protection duration.
- Existing clinical data is largely based on European MSM populations.

Expected impact:

- Extend MpoxVax trial to DRC, Tanzania and Uganda to assess MVA-BN vaccine immune responses.
- Evaluate immune biomarkers and validated assays to distinguish infection- vs vaccine-induced immunity and strengthen regional clinical trial capacity.



Coordinator:
University College Dublin, Ireland

Scientific leader:
Makerere University Lung Institute, Uganda

Countries: **Ireland, Tanzania, UK, Uganda, DRC**

Funding: **€1,371,783.75**

Project length: **2024 – 2027**

<https://www.mpoxvaxafrivac.eu/>
https://www.global-health-edctp3.europa.eu/projects/mpoxvax-afrivac_en

Project highlight: EACCR4

A Ugandan research organisation provides scientific leadership in a regional network strengthening clinical research capacity across East Africa.

The challenge:

- Low clinical trial representation in sub-Saharan Africa delays access to safe, effective medical innovations.
- Weak infrastructure and shortage of trained staff limit clinical trial capacity.

Expected impact:

- Expand a 23-partner clinical research network across 13 countries.
- Strengthen infrastructure, labs, data systems and outbreak-ready clinical trial capacity.
- Train researchers and clinicians and advance research on HIV, malaria and NTDs.



Coordinator:
European & Developing Countries Clinical Trials Partnership, Netherlands

Scientific leader:
Uganda National Health Research Organisation, Uganda

Countries: **Netherlands, Uganda, Somalia, Tanzania, Zambia, Rwanda, Kenya, Denmark, UK, Germany, Norway, Sweden, DRC**

Funding: **€12,751,648.96**

Project length: **2026 – 2030**

https://www.global-health-edctp3.europa.eu/projects/eaccr4_en

Project highlight: ACT-PREP

A Ugandan university provides scientific leadership in a regional network strengthening outbreak-ready clinical trial capacity across sub-Saharan Africa.

The challenge:

- Weak health systems and limited outbreak surveillance/response capacity in sub-Saharan Africa.
- Poor integration of research into outbreak response, despite existing regional expertise.

Expected impact:

- Build outbreak-ready clinical trial systems by integrating preparedness into national health systems.
- Train 700+ researchers and health professionals.
- Upgrade labs, data systems, and regulatory capacity to enable faster, coordinated outbreak research and response.



Coordinator:
European & Developing Countries Clinical Trials Partnership, Netherlands

Scientific leader:
Makerere University, Uganda

Countries: **Netherlands, Uganda, Somalia, DRC, Tanzania, Ethiopia, Sweden, Germany, Rwanda, Senegal, South Sudan**

Funding: **€12,751,864.50**

Project length: **2026 – 2031**

https://www.global-health-edctp3.europa.eu/projects/act-prep_en

Project highlight: ResTick

A Ugandan university provides scientific leadership for strengthening surveillance and control of Crimean-Congo haemorrhagic fever across sub-Saharan Africa.

The challenge:

- Tick ecology is poorly mapped, and climate change is altering their distribution and increasing exposure risk.
- Frequently acquired following contact with livestock or wild animals, CCHF has a fatality rate of up to 40%.

Expected impact:

- Characterise around 5,000 ticks a year across SSA.
- Provide new tools for detecting CCHF virus infections, to facilitate disease detection and control.
- Decipher the role of acaricide resistance on transmission dynamics of CCHF virus.



Coordinator:

Idryma Technologias Kai Erevnas, Greece

Scientific leader:

Makerere University, Uganda

Countries: **Greece, Uganda, Ethiopia, South Africa, Benin, Togo, Burkina Faso, Côte d'Ivoire**

Funding: **€6,130,555**

Project length: **2025 – 2028**

<https://restick.eu/>

https://www.global-health-edctp3.europa.eu/projects/restick_en

Project highlight: SUPPORT

A Ugandan university research institute provides scientific leadership in a project building career pathways for African researchers in paediatric HIV.

The challenge:

- Limited career development opportunities for health researchers in sub-Saharan Africa.
- Few structured pathways to integrate additional researchers into international research partnerships.

Expected impact:

- Provide training and mentorship for eight early-career researchers and five mid-career postdoctoral researchers in paediatric HIV.
- Generate additional evidence on treatment and care of children living with HIV in SSA.



Coordinator:
Universidad Complutense de Madrid, Spain

Scientific leader:
Makerere University Lung Institute, Uganda

Countries: **Spain, Uganda, Italy, France, Netherlands, Zimbabwe, Mozambique, Senegal, Zambia, UK**

Funding: **€5,081,593.75**

Project length: **2024 – 2028**

https://www.global-health-edctp3.europa.eu/projects/support_en

Project highlight: PROTECT

A Ugandan research organisation provides scientific leadership for building vaccine safety surveillance for maternal immunisation in Africa.

The challenge:

- Neonatal deaths remain high, highlighting the need for maternal vaccination against RSV and GBS.
- Limited monitoring systems make it challenging to ensure vaccine safety for pregnant women.

Expected impact:

- Create an international platform for tracking the safety of new vaccines used in African populations.
- Establish a network of sites able to conduct phase III and IV maternal vaccination trials.
- Provide data on GBS burden to guide national vaccine decisions.

PROTECT



Coordinator:

Instituto de Salud Global de Barcelona, Spain

Scientific leader:

MU-JHU Care LTD, Uganda

Countries: **Spain, Uganda, Kenya, Malawi, Mozambique, Belgium, Germany, UK**

Funding: **€3,271,990.50**

Project length: **2024 – 2027**

https://www.global-health-edctp3.europa.eu/projects/protect_en

Thank you!

Global Health EDCTP3



Co-funded by
the European Union

